Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.60 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16111449 | 0.81 | TP53 (0.61) | TP53THRBMAPTUSP2ALDH1A1 | |
| SCHEMBL5507606 | 0.81 | OPRM1 (0.48) | OPRM1OPRD1OGFRL1OPRK1TP53 | |
| SCHEMBL5506316 | 0.79 | OPRM1 (0.51) | OPRM1OPRD1OGFRL1OPRK1GBA1 | |
| SCHEMBL5238291 | 0.76 | OPRM1 (0.52) | OPRM1OPRD1OGFRL1OPRK1GBA1 | |
| SCHEMBL24951551 | 0.76 | GBA1 (0.56) | OPRM1OPRD1OGFRL1GBA1MAPT | |
| SCHEMBL30819461 | 0.76 | GBA1 (0.56) | OPRM1OPRD1OGFRL1GBA1MAPT | |
| SCHEMBL5496623 | 0.76 | OPRM1 (0.53) | OPRM1OPRD1OGFRL1OPRK1MAPT | |
| SCHEMBL853237 | 0.75 | OGFRL1 (1.00) | OPRM1OPRD1OGFRL1OPRK1 | |
| SCHEMBL31143019 | 0.74 | HTR3B (0.57) | OPRM1OPRD1OGFRL1GBA1MAPT | |
| SCHEMBL405743 | 0.74 | HTR3B (0.57) | OPRM1OPRD1OGFRL1GBA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789050-A1 | NOVEL QUINOXALINONE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006016278-A1 | NOVEL QUINOXALINONE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030566-A1 | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY, LLC | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030566-A1 | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | SLC6A2, SLC18A2, SLC6A3 | OPRM1 61/4885OPRD1 53/4885OGFRL1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.